Order a test

RGCC CAMBISeq®

RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into cancer.

The CAMBISeq® – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their sensitivity to immunotherapy. The results can predict how well a patient will respond to types of immunotherapy.

RGCC CAMBISeq® is suitable for all patients who have a confirmed cancer diagnosis. The test can be used by clinicians to identify the best, and most effective, combinations of cancer treatments.

Sample of the reportOrder a test

Test Details

Sample Type

Blood, tissue, FFPE Tissue (Formalin-Fixed Paraffin-Embedded)

Analysis period

Approx. 2–3 weeks

Cancer type

All types of Cancers

Final results

2–4 weeks

Sample Size

Blood: 7–10 ml peripheral whole blood, Fresh tissue: Minimum 400mg, FFPE: Minimum 100mg (or 1 block)

Price*

3100€

* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.

Find out more about the science behind RGCC tests

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more